Table 2.
Impact on stage | 19 (52.8%) |
---|---|
Upstaging Downstaging |
10 9 (including 2 false negatives) |
Impact on therapy | 20 (55.6%) |
Omit further Tx Start cold octreotide Re-surgery Palliative RT |
6 11 2 1 |
No impact on therapy | 11 (30.6%) |
Unknown impact because lost to follow-up | 5 (13.9%) |